Bayer markets $14.2B loan for Merck consumer unit; Adcock sinks in H1; CIA ditches vaccination ruses;

@FiercePharma: Top-read on FiercePharma Mon: How did AstraZeneca make the Pfizer bid a Harry vs. Voldemort story? Story | Follow @FiercePharma

@TracyStaton: Some $AZN investors are balking at the board's $PFE snub. Others are practically high-fiving Chairman Johannson. More from Reuters | Follow @TracyStaton

@EricPFierce: FDA inspectors find 10 trash bags of partially destroyed raw data CGMP records at Sun Pharma plant. Article via FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Kymab, Gates Foundation to team up for malaria, HIV antigen discovery. More from FierceVaccines | Follow @CarlyHFierce

> Bayer is marketing a $14.2 billion loan backing its proposed buyout of Merck's ($MRK) consumer unit. Report

> The U.K.'s cost watchdog has recommended Johnson & Johnson's ($JNJ) Type 2 diabetes med Invokana for use in Britain's National Health Service. More

> South Africa's Adcock Ingram blamed an H1 loss on costs related to a failed takeover by Chile's CFR. Report

> Takeda execs hid the cancer risks of diabetes med Actos to protect billions of dollars in sales, a lawyer for two women argued in closing arguments in a Las Vegas trial. More

> Jazz Pharmaceuticals ($JAZZ) has named Russell Cox as its COO. Release

> Merck KGaA is investing €50 million ($68.5 million) in its Italian production site in Bari. Release (PDF)

Medical Device News

@FierceMedDev: Medtronic and Edwards Lifesciences settle the score in ongoing patent feud. More | Follow @FierceMedDev

@VarunSaxena2: Device companies win in survey of top places to work in medical sales. 53% of respondents prefer them. Story (reg. req.) | Follow @VarunSaxena2

@MichaelGFierce: From Harvard: Herpes-loaded stem cells used to kill brain tumors. News | Follow @MichaelGFierce

@EmilyWFierce: "Drinkable books" double as a water filter, educate developing world about deadly waterborne illnesses. More | Follow @EmilyWFierce

> FDA approves iPad-based blood loss monitor. Item

> HistoSonics banks $14M for ultrasound prostate tech. More

> Medtronic's earnings plunge 54% due to litigation charge. Story

Biotech News

@FierceBiotech: Angry AstraZeneca investors may hold the only key to a Pfizer deal. Story | Follow @FierceBiotech

@JohnCFierce: If I was counseling Ian Read today, I'd say wipe the smug look off your face, go buy something significant and then break up the co. Pronto. | Follow @JohnCFierce

@DamianFierce: More biotech insider trading as SEC accuses investigators in a halted GTx trial. More | Follow @DamianFierce

@EmilyMFierce: Animal model that mimics hep B, C in humans could spur new treatments. Article | Follow @EmilyMFierce

> Clovis bags 'breakthrough' tag for its cancer drug as ASCO's spotlight awaits. More

> R.I.P.: Merck and Endocyte yank vintafolide app. Item

> Pioneering CAR-T biotech upstart plans to leapfrog into a $115M IPO. News

Pharma Manufacturing News

> FDA sends marshals in to seize drugs from unit of Alkem. More

> Roche investments for boosting manufacturing now exceed $1B. Story

> Novasep gets FDA OK for HPAPI expansion in France. Article

> Abbott expands manufacturing in Latin America with CFR deal. News

> Manufacturing continues to boost WuXi PharmaTech sales. Item

> FDA balks at accepting all EU plant inspections. More

Biotech Research News

> NIH addresses sex bias in preclinical research. Item

> Natural antibacterial clay could fight MRSA, other infections. More

> Anti-MERS therapies ID'd among existing drugs. Story

> Animal model that mimics hep B, C in humans could spur new treatments. Article

> CDC scientist: MERS doesn't present pandemic risk, but other diseases might. More

> Nanocarriers that harness fungus traits could deliver drugs to brain. News

And Finally... The CIA will no longer use vaccination programs as a cover-up for spying operations. More (sub. req.)

Suggested Articles

Talk about making pharma history. Merck's Keytruda has racked up yet another first-of-its-kind approval, this time in a combo with Eisai’s Lenvima.

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.